IP Verse

Methods For Engineering T Cells For Immunotherapy By Using Rna-Guided Cas Nuclease System - EP3004337

The patent EP3004337 was granted to Cellectis on Aug 2, 2017. The application was originally filed on Apr 1, 2014 under application number EP14714278A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3004337

CELLECTIS
Application Number
EP14714278A
Filing Date
Apr 1, 2014
Status
Opposition Rejected
Feb 28, 2020
Grant Date
Aug 2, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BARKER BRETTELLMay 1, 2018ADMISSIBLE

Patent Citations (32) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2013US58005-
DESCRIPTIONUS2006121005
DESCRIPTIONUS2013065314
DESCRIPTIONUS4474893
DESCRIPTIONUS4683195
DESCRIPTIONUS5858358
DESCRIPTIONUS5883223
DESCRIPTIONUS6010613
DESCRIPTIONUS6352694
DESCRIPTIONUS6534055
DESCRIPTIONUS6642043
DESCRIPTIONUS6692964
DESCRIPTIONUS6797514
DESCRIPTIONUS6867041
DESCRIPTIONUS6887466
DESCRIPTIONUS6905680
DESCRIPTIONUS6905681
DESCRIPTIONUS6905874
DESCRIPTIONUS7067318
DESCRIPTIONUS7144575
DESCRIPTIONUS7172869
DESCRIPTIONUS7175843
DESCRIPTIONUS7232566
DESCRIPTIONWO2004083379
DESCRIPTIONWO2013126712
DESCRIPTIONWO2013176915
DESCRIPTIONWO2014011988
DESCRIPTIONWO9424277
INTERNATIONAL-SEARCH-REPORTWO2013074916
INTERNATIONAL-SEARCH-REPORTWO2013176915
OPPOSITIONWO2013074916
OPPOSITIONWO2013176915

Non-Patent Literature (NPL) Citations (17) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- WANG HAOYI ET AL, "One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering", CELL, CELL PRESS, US, (20130502), vol. 153, no. 4, doi:10.1016/J.CELL.2013.04.025, ISSN 0092-8674, pages 910 - 918, XP028538358
EXAMINATION- Y Zhao ET AL, "High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation", Molecular Therapy, GB, (20060101), vol. 13, no. 1, doi:10.1016/j.ymthe.2005.07.688, ISSN 1525-0016, pages 151 - 159, XP055267774
OPPOSITION- WANG et al., "One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering", Cell, (20130000), vol. 153, no. 4, pages 1 - 9,S1-S4, XP055485583-
OPPOSITION- POIROT et al., "128 T- Cell Engineering for Adoptive Immunotherapy Using TAL- Effector Nucleases (TALEN)", Molecular Therapy, (20130400), vol. 21, no. S1, page S38, XP055485507
OPPOSITION- WEI et al., "TALEN or Cas9 - Rapid, Efficient and Specific Choices for Genome Modifications", Journal of Genetics and Genomics, (20130600), vol. 40, no. 6, pages 281 - 289, XP055071686
OPPOSITION- GAJ et al., "ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering", Trends in Biotechnology, (20130000), vol. 31, no. 7, pages 397 - 405, XP028571313
OPPOSITION- ZHAO et al., "High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation", Mol. Ther., (20060000), vol. 13, no. 1, pages 151 - 159, XP055267774
OPPOSITION- RAN et al., "In vivo genome editing using Staphylococcus aureus Cas9", HHS Public Access Author M, (20150000), vol. 520, no. 7546, pages 1 - 28, XP055485643
OPPOSITION- CHO et al., "Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease (includes Supplementary information)", Nature Biotechnology, (20130000), vol. 31, no. 3, pages 230 - 232,1-11, XP002699850
OPPOSITION- MALI et al., "Cas9 as a versatile tool for engineering biology", Nature Methods, (20130000), vol. 10, no. 10, pages 957 - 963, XP002718606
OPPOSITION- KOCHENDERFE R et al., "Treating B- cell cancer with T cells ex pressing anti- CD 19 chimeric antigen receptors", Nature reviews clinical oncology, (20130500), vol. 10, no. 5, pages 267 - 276, XP009170183
OPPOSITION- EBINA et al., "Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus", Scientific Reports, (20130800), vol. 3, pages 1 - 7, XP055110157
OPPOSITION- MALI et al., "RNA-Guided Human Genome Engineering via Cas9", Science, (20130000), vol. 339, no. 6121, pages 823 - 826, XP055111247
OPPOSITION- JENA et al., "Redirecting T- cell specificity by introducing a tumor-specific chimeric antigen receptor", Blood, (20100819), vol. 116, no. 7, pages 1035 - 1044, XP055021403
OPPOSITION- TORIKAI et al., "A foundation for universal T- cell based immunotherapy: T cells engineered to express a CD 19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR", Blood, vol. 119, no. 24, (20120000), pages 1 - 17, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382929/?report=printable, XP055485469
OPPOSITION- LLOYD et al., "Beyond the Antigen Receptor : Editing the Genome of T-Cells for Cancer Adoptive Cellular Therapies", Frontiers in Immunology, (20130805), vol. 4, pages 1 - 7, XP055110101
OPPOSITION- MANJUNATH et al., "Newer Gene Editing Technologies toward HIV Gene Therapy", Viruses, (20130000), vol. 5, no. 11, pages 2748 - 2766, XP055110267

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents